Longer PET Acquisition Time Increases FDG-Avid Lymph Node Detection in Rectal Cancer
The procedure also upstaged several subjects.
Longer PET acquisition times during PET/MRI for rectal cancer increases the number of FDG-avid lymph nodes detected without increasing scan time, according to a study published in the American Journal of Roentgenology.
Researchers from the University of California, San Francisco, and the San Francisco VA Medical Center, sought to determine if extended PET acquisition times in the pelvis during PET/MRI increase detection rates of potentially metastatic lymph nodes in patients with rectal cancer.
Twenty-two patients with biopsy-proven rectal cancer participated in the study. All underwent imaging via simultaneous 3-T time-of-flight PET/MRI; seven underwent two separate PET/MRI examinations. This provided a total of 29 studies. Each examination included both a whole-body PET/MRI and a dedicated pelvic PET/MRI with both 3- and 15-minute PET acquisitions for the pelvis. Three radiologists interpreted each examination with PET only, MRI only, then combined PET and MRI examinations, using all available images. Additionally, the 3- and 15-minute PET acquisitions of the pelvis were reviewed separately by a single radiologist.
Related article: PET/MRI Motion Correction Aids in Quantifying, Detecting PET-Avid Lesions
The results showed that 94 lymph nodes were identified as abnormal on PET, all with MRI anatomic correlates. Of these:
- 37 (39.4%) were seen only on the dedicated 15-minute acquisition
- 57 (60.6%) nodes measured 5 mm or less, including 29 (30.9%) seen only on the 15-minute acquisition
- 31 (33.0%) nodes measured 5.1–10 mm, including eight (25.8%) seen only on the 15-minute acquisition
Of the 17 subjects imaged for initial staging, 11 (64.7%) were upstaged as a result of the increased PET acquisition time (10 from N1 to N2 and one from N0 to N1).
The researchers concluded that longer PET acquisition times during PET/MRI for rectal cancer increased the number of FDG-avid lymph nodes detected without increasing scan time.
Meta-Analysis Shows No Difference Between bpMRI and mpMRI in Ruling Out csPCa
March 6th 2025In an 18-study meta-analysis involving over 4,600 patients, researchers found that bpMRI and mpMRI had equivalent pooled negative predictive value (NPV) of 92 percent for clinically significant prostate cancer (csPCa).
Is MRI Contrast Enhancement Necessary for Long-Term Monitoring of Diffuse Glioma?
March 4th 2025In a comparison of contrast-enhanced T1-weighted (CET1w) MRI (and T2-weighted MRI/FLAIR imaging, researchers found that only three out of 82 cases of glioma progression were solely detected with CET1w MRI.
Can Deep Learning Ultra-Fast bpMRI Have an Impact in Prostate Cancer Imaging?
March 3rd 2025A deep learning-enhanced ultra-fast bpMRI protocol offered similar sensitivity for csPCa as mpMRI with an 80 percent reduction in scan time, according to research findings presented at the European Congress of Radiology (ECR) conference.
